Translational and Clinical Pharmacology · 2017 · 11 citations · 10 references
MedicinePharmacokineticsPharmacologyClinical PharmacologyDrug InteractionsPharmacokinetic ModelingDrug-drug InteractionsPharmacokinetic Drug InteractionsDrug-drug Interaction EvaluationGeometric Mean RatioLow-density Lipoprotein Cholesterol LoweringPharmacokinetic Interaction AnalysisPharmacokinetic Interaction AssessmentPharmacokinetic Interaction MechanismsPharmacokinetic Study DesignWilliams Designs
) of atorvastatin when administered with and without ezetimibe were 1.1087 (0.9799-1.2544) and 1.1154 (1.0079-1.2344), respectively. The corresponding values for total ezetimibe were 1.0005 (0.9227-1.0849) and 1.0176 (0.9465-1.0941). There was no clinically significant change in safety assessment related to either atorvastatin or ezetimibe. Co-administration of atorvastatin and ezetimibe showed similar PK and safety profile compared with each drug alone. The PK interaction between two drugs was not clinically significant in healthy Korean volunteers.
10
Paul S. Jellinger, Yehuda Handelsman, Paul D. Rosenblit et al. · Endocrine Practice · 2017 · 1.1K citations
Paul S. Jellinger, Yehuda Handelsman, Paul D. Rosenblit et al. · Endocrine Practice · 2017 · 208 citations